PharmaTher Holdings Ltd. (PHRM.CN)
| Previous Close | 0.1500 |
| Open | 0.1400 |
| Bid | 0.1400 x N/A |
| Ask | 0.1500 x N/A |
| Day's Range | 0.1350 - 0.1450 |
| 52 Week Range | 0.1050 - 1.2400 |
| Volume | |
| Avg. Volume | 261,446 |
| Market Cap | 12.691M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0530 |
| Earnings Date | Oct 27, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
PharmaTher Announces Positive Results from Study of KETABET™ for Depression
KETABET™ (Ketamine and Betaine) shown effectiveness as measured by the Clinician Administered Dissociative States Scale Study results are adequate to give an effect size in powering a placebo-controlled clinical study PharmaTher planning a Phase 2 clinical study to incorporate KETABET™ in its proprietary microneedle patch for depression TORONTO, June 07, 2022 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a leader in specialty ketamine ph
- GlobeNewswire
PharmaTher To Develop and Commercialize Novel Wearable Ketamine Delivery Device in Collaboration with CCBIO
CCBIO’s Felice Dose on-body wearable device CCBIO’s Felice Dose on-body wearable device CCBIO’s Felice Dose on-body wearable device prototype worn on a person CCBIO’s Felice Dose on-body wearable device prototype worn on a person Wearable ketamine delivery device complements PharmaTher’s ketamine product portfolio, including injectable, intravenous, and microneedle patch PharmaTher aims to become a leader in specialty ketamine products for mental health, neurological and pain disorders TORONTO,
- GlobeNewswire
PharmaTher Announces Grant of U.S. Patent on Formulation and Production Process of Ketamine and Ketamine Analogs
TORONTO, May 05, 2022 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a leader in specialty ketamine pharmaceuticals, is pleased to announce that the United States Patent and Trademark Office granted US Patent No: 11,286,230, titled “Ketamine Flow Synthesis” (the “Patent”), which refers to a continuous-flow process technology for the preparation of ketamine and ketamine analogs. The Company gained exclusive worldwide development and commer
